2-(4-Aminopiperidin-1-yl)acetaldehyde;hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-(4-Aminopiperidin-1-yl)acetaldehyde;hydrochloride
• 英文别名: 2-(4-aminopiperidin-1-yl)acetaldehyde;hydrochloride
• 化学式: C7H15ClN2O
• 分子量: 178.66
• InChiKey: DTWZOFYCAZFAQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.03
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  46.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] CRYSTALLINE SALTS OF (S)-6-((1-ACETYLPIPERIDIN-4-YL)AMINO)-N-(3-(3,4-DIHYDROISOQUINOLIN-2(1H)-YL)-2-HYDROXYPROPYL)PYRIMIDINE-4-CARBOXAMIDE<br/>[FR] SELS CRISTALLINS DE (S)-6-((1-ACÉTYLPIPÉRIDIN-4-YL)AMINO)-N-(3-(3,4-DIHYDROISOQUINOLIN-2(1H)-YL)-2-HYDROXYPROPYL)PYRIMIDINE-4-CARBOXAMIDE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015198229A1

  公开（公告）日：2015-12-30

  Disclosed are novel crystalline salts of (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.

  揭示了(S)-6-((1-乙酰基哌啶-4-基)氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟基丙基)嘧啶-4-甲酰胺的新型晶体盐，以及含有该盐的药物组合物。还揭示了其制备方法和使用方法。
• PRMT5 INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：EP2935222A2

  公开（公告）日：2015-10-28
• CRYSTALLINE SALTS OF (S)-6-((1-ACETYLPIPERIDIN-4-YL)AMINO)-N-(3-(3,4-DIHYDROISOQUINOLIN-2(1H)-YL)-2-HYDROXYPROPYL)PYRIMIDINE-4-CARBOXAMIDE
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP3160958A1

  公开（公告）日：2017-05-03
• [EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100719A2

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5 mediated disorders are also described.
• [EN] USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR<br/>[FR] UTILISATION DE BIOMARQUEURS DANS L'IDENTIFICATION DE PATIENTS QUI SERONT SENSIBLES À UN TRAITEMENT AVEC UN INHIBITEUR DE PRMT5
  申请人：MERCK SHARP & DOHME

  公开号：WO2021126999A1

  公开（公告）日：2021-06-24

  The present invention includes methods of identifying a patient who will likely be responsive to treatment with a protein arginine N-methyltransferase 5 inhibitor, or a pharmaceutically acceptable salt thereof, and methods of treating the same.